Skip to main content
. 2014 Sep 16;6(5):53. doi: 10.1186/s13195-014-0053-6

Table 6.

Clinical and neuropathological criteria

Study Sample Database Neuropathological criteria Autopsy Dementia criteria
McKeith et al ., 1992 [[20]]
AD 37
Newcastle, UK
AD: plaque/tangle quantification, H + E, CFV, Loyez, Palmgren.
All
DLB: proposed consensus (1992)
SDLT 21
LB: H + E, pholxine, erythrosin
Ballard et al ., 1996 [[17]]
AD 53
West Midlands and Bristol, UK
 
0
AD: NINCDS/ADRDA (1984)
SDLT 7
DLB: McKeith, operational criteria for senile dementia of Lewy body type (1992)
VaD 14
Ballard et al., 1998 [[21]]
AD 30
Newcastle General Hospital, UK
AD: CERAD, plaque – Braunmuhl stain, tangle – modified Palmgren
19
AD: NINCDS/ADRDA (1984)
DLB 42
DLB: McKeith, operational criteria for senile dementia of Lewy body type (1992)
LB: consensus criteria (1996), ubiquitin, anti-tau2, anti-Alz50, anti-AT8 to detect and distinguish cortical LB
Olichney et a l., 1998 [[3]]
AD 148
Cohort from:
AD: CERAD, ADRC
All
AD: NINCDS/ADRDA (1984),
LBV 40
Univeristy of California, San Diego Alzheimer’s Disease Research Center, USA;
LB: ubiquitin, H + E (brainstem, cerebral cortex)
DSM-III for dementia
CERAD centers, multinational
Heyman et al ., 1999 [[18]]
AD 74
Subjects with premortem diagnosis of probable and possible AD from 24 centers participating in CERAD, 1986 to 1995, USA
AD: CERAD
All
AD: NINCDS/ADRDA (1984)
AD/LBV 27
LB: consensus criteria (1996), modified (brainstem, limbic/transitional and noecortical).
Lopez et al ., 2000 [[22]]
AD 98
University of Pittsburg 1983 to 1998, USA
AD: CERAD, NIA-RI
All
AD: NINCDS/ADRDA (1984)
AD/DLB 44
LB: H + E, ubiqutin (SN, neocortex, limbic areas)
DLB: consensus criteria (1996)
Stern et al . 2001 [[23]]
AD 32
From cohort of 236 patients with probable AD
AD: CERAD
All
AD: NINCDS/ADRDA (1984)
LBV 19
LB: semi quantitative ubiquitin (SN, hippocampus, cingulate gyrus, insula cortex)
Recruited:
Columbia University College, New York, USA
Johns Hopkins University, Baltimore, USA
Massachusetts General Hospital, Boston, USA
Ballard et al ., 2001 [[24]]
AD 101
Cohort of 227 patients
AD: CERAD, plaque - Braunmuhl stain, tangle - modified Palmgren
50
AD: NINCDS/ADRDA (1984)
DLB 64
Institute of the Health of the Elderly (IHE), Newcastle, UK
DLB: consensus criteria (1996)
VaD 38
LB: consensus criteria (1996), ubiquitin, anti-tau2, anti-Alz50, anti-AT8 to detect and distinguish cortical LB
Helmes et al ., 2003 [[25]]
AD 15
University of Western Ontario Dementia Study, Canada
No criteria are referred to. Only referred to LB staining methods (Bielschovsky, anti-ubiquitin, anti-synuclein).
All
Not specified.
AD/DLB 8
DLB 7
Johnson et al ., 2005 [[26]]
AD 66
Washington University, from 1979, USA
AD: NIA-RI quantification of diffuse and neuritic depositions in 10 cortical regions
All
AD: NINCDS/ADRDA (1984)
AD/DLB 57
DLB: consensus criteria (1996) or McKeith, operational criteria for senile dementia of Lewy body type (1992)
DLB 9
LB: synuclein
Kraybill et al ., 2005 [[15]]
AD 48
Cohort from University of Washington/Group Health Cooperative Alzheimer’s Disease Patient Registry, USA
AD: CERAD, Braak stages > IV
All
AD: NINCDS/ADRDA (1984)
AD/LBP 65
LB/AD: AD + synuclein (amygdala, SN)
DLB: missing criteria because study was started before the consensus criteria for DLB was established.
LBP 22
LB: Braak stages < III, synuclein (amygdala, SN)
Stavitsky et a l., 2006 [[19]]
AD 55
Cohort of the Predictors Study, 1997:
AD: CERAD
12
AD: NINCDS/ADRDA (1984)
DLB 28
LB: semi quantitative ubiquitin (hippocampus, cingulate gyrus, insula cortex)
DLB: consensus criteria (1996)
Columbia University
Johns Hopkins University,
Massachusetts General Hospital, USA
Williams et al ., 2006 [[27]]
AD 252
Cohort from Washington University, USA
AD: NIA-RI quantification of diffuse and neuritic depositions in 10 cortical regions
All
AD: NINCDS/ADRDA (1984)
DLB 63
DLB: consensus criteria (1996)
LB: synuclein
Hamilton et al ., 2008 [[28]]
AD 44
University of California, Alzheimer’s disease center San Diego, 1985 to 2002, USA
AD: modified Braak staging, NIA-RI (1997) and CERAD (1991)
All
AD: NIA-RI and CERAD (1988)
DLB 22
DLB: consensus criteria (1996)
LB: H + E, ubiquitin (1996) synuclein (2005)
Hanyu et al ., 2009 [[29]]
AD 111
Memory Clinic of Tokyo Medical University, 2000 to 2006, Japan
 
0
AD: NINCDS/ADRDA (1984)
DLB 56
DLB: consensus criteria (1996)
Nelson et al ., 2009 [[16]]
AD 107
National Alzheimer’s Coordinating Center (NACC) Registry - 31 AD centers in USA,
AD: NIA-RI
All
AD: CERAD (1988)
AD/DLB 27
University of Kentucky Alzheimer’s Disease Center, USA
LB: Braak staging and CERAD
DLB: consensus criteria (1996)
DLB 9
Wood et a l., 2012 [[30]]
AD 16
Newcastle University, UK
 
0
AD: NINCDS/ADRDA (1984)
DLB 12
DLB: consensus criteria (2005) or (1996)
Walker et al . 2012 [[31]] AD 100
40 European sites 123I-FTP-SPECT as verifying method 0 AD: NINCDS/ADRDA (1984)
DLB 58 DLB: consensus criteria (1996)

AD, Alzheimer’s disease; ADRC, Alzheimer’s Disease Research Center; CERAD, The Consortium to Establish a Registry for Alzheimer's Disease; CFV, creasyl fast violet; DLB, dementia with Lewy bodies; H + E, hematoxylin and eosin staining; I-FTP-SPECT, ioflupane single-photon emission computed tomography; LB Lewy body; LBV, Lewy body variant; LBP, Lewy body pathology; NIA-RI, National Institute on Aging-Reagan; NINCDS/ADRDA, National Institute of Neurological and Communication Disorders and Stroke/Alzheimer’s Disease and Related Disorders Association; SDLT, senile dementia of Lewy body type; SN, substantia nigra.